Schachtschabel U, Pavlinkova G, Lou D, Köhler H
Markey Cancer Center, University of Kentucky, Lexington 40536-0096, USA.
Cancer Gene Ther. 1996 Nov-Dec;3(6):365-72.
The targeted introduction of therapeutic genes into malignant cells based on receptor mediated endocytosis of ligand-DNA conjugates recently was established as a transfection system and provides a promising strategy for cancer therapy. Antiidiotype antibodies could be of particular interest for this approach because their immunoglobulin receptor idiotypes represent highly specific tumor markers. Their safe and specific applicability in vivo, alone or as immunotoxins, has been proven in clinical trials for passive immunotherapy and vaccination strategies. For these reasons we have explored the utility of antiidiotype antibodies for gene delivery systems using the reporter genes beta-galactosidase and luciferase. Two monoclonal antibodies, SIC5 and 5D10, specific for B-lymphoma cell lines, which represent models for murine plasmacytoma (38C13) and human non-Hodgkin's lymphoma (SU-DHL-4) have been covalently linked to polylysine via the heterobifunctional cross-linker SPDP. Highly efficient uptake and internalization of the immunoconjugates have been shown by fluorescence microscopy and fluorescence-activated cell sorting (FACS) analysis. Successful transfections have been shown at the RNA and the reporter gene level (beta-galactosidase, luciferase) using different promoter/enhancer systems. Beta-galactosidase activity was detected by flow cytometry (FACS-gal) analysis for both cell lines, and SU-DHL-4 cells showed significant luciferase activity.
